Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 665 |
| Active Pipeline (Recruiting Now) | 365 (196) |
| Completed vs Stopped Early | 60 / 30 (4.5%) |
| Median Closed Actual Enrollment | 54 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong | 319 |
| The First Affiliated Hospital of Sun Yat-sen University | Guangzhou, Guangdong | 21 |
| Hunan Cancer Hospital | Changsha, Hunan | 13 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05918094 | Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophag | Phase III | RECRUITING |
| NCT06726421 | Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study) | Phase III | RECRUITING |
| NCT07477626 | Radiotherapy After Prostatectomy for Node Positive Prostate Cancer | Phase III | RECRUITING |
| NCT06455410 | GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma | Phase II | RECRUITING |
| NCT06301165 | TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Sun Yat-sen University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.